HAO1 and primary hyperoxaluria type 1: Lumasiran, approved by the European Union and the United States in November 2020 for the treatment of PH1 patients of all ages, is a liver-directed RNA interference therapy, targeting the messenger RNA of glycolate oxidase (44), which can reduce the production of hepatic oxalate to achieve the purpose of treatment.